NASDAQ:AVROAvrobio Stock Price, Forecast & News

Avrobio's stock was trading at $18.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVRO stock has increased by 12.2% and is now trading at $20.22. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avrobio.

Avrobio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Avrobio.

Avrobio Inc (NASDAQ:AVRO) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.77) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.11. View Avrobio's earnings history.

7 brokerages have issued 12-month target prices for Avrobio's stock. Their forecasts range from $13.00 to $43.00. On average, they anticipate Avrobio's stock price to reach $33.60 in the next year. This suggests a possible upside of 66.2% from the stock's current price. View analysts' price targets for Avrobio.

Media coverage about AVRO stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avrobio earned a news sentiment score of 0.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutAvrobio.

Avrobio saw a decrease in short interest in May. As of May 15th, there was short interest totaling 1,340,000 shares, a decrease of 26.4% from the April 30th total of 1,820,000 shares. Based on an average trading volume of 388,200 shares, the short-interest ratio is currently 3.5 days. Currently, 4.7% of the company's shares are short sold. View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Regenxbio (RGNX), I-Mab (BDTX), Cortexyme (CRTX), Coherus Biosciences (CHRS) and Beam Therapeutics (BEAM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Gilead Sciences (GILD), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB) and Zynerba Pharmaceuticals (ZYNE).

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Avrobio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (7.19%), BlackRock Inc. (5.43%), Eventide Asset Management LLC (5.29%), Camber Capital Management LP (3.75%), Aisling Capital Management LP (2.80%) and Wellington Management Group LLP (2.46%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View institutional ownership trends for Avrobio.

AVRO stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, BNP Paribas Arbitrage SA, Squarepoint Ops LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Avrobio company stock in the last year include Christopher Paige, and Geoffrey Mackay. View insider buying and selling activity for Avrobio.

AVRO stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Vivo Capital LLC, Wellington Management Group LLP, Eventide Asset Management LLC, JPMorgan Chase & Co., Driehaus Capital Management LLC, Burrage Capital Management LLC, and UBS Group AG. View insider buying and selling activity for Avrobio.

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $20.22.

Avrobio has a market capitalization of $728.63 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe.

The official website for Avrobio is www.avrobio.com.

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]